Clinical Trial Update: Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial suggests that a sedating antidepressant improves driving safety in adults with major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Snippet

Sponsor: University Health Network, Toronto | Conditions: Depression, Excessive Daytime Sleepiness | Phase 2 | Status: COMPLETED